Scopus BioPharma (NASDAQ:SCPS – Get Free Report) will likely be releasing its resultson Wednesday, June 3rd. Analysts expect Scopus BioPharma to post earnings of ($0.23) per share for the quarter.
Scopus BioPharma Stock Performance
Shares of SCPS opened at $0.00 on Wednesday. Scopus BioPharma has a 1 year low of $0.00 and a 1 year high of $0.01.
Scopus BioPharma Company Profile
Scopus BioPharma, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for central nervous system disorders. The company’s research efforts are aimed at addressing unmet medical needs in neuropathic pain, migraine and mood disorders by leveraging proprietary small-molecule platforms designed to modulate key neural pathways.
The company’s product pipeline comprises both clinical- and preclinical-stage candidates. Its lead programs include small-molecule compounds intended to provide relief in patients suffering from chronic neuropathic pain and episodic migraine.
Featured Stories
- Five stocks we like better than Scopus BioPharma
- Banks Are Buying Back Stock Hand Over Fist, Including These 3 Names
- 2 Aluminum Stocks Poised for Big Tariff-Related Gains
- AutoZone’s Pullback Sets Up a Long-Term Buying Opportunity
- AST SpaceMobile’s June Launch Plan Puts Its 2026 Satellite Goal Back in Focus
Receive News & Ratings for Scopus BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scopus BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
